Peters G J, Nadal J C, Laurensse E J, de Kant E, Pinedo H M
Department of Oncology, Free University Hospital, Amsterdam, The Netherlands.
Biochem Pharmacol. 1990 Jan 1;39(1):135-44. doi: 10.1016/0006-2952(90)90657-7.
Brequinar sodium (DUP-785) is a potent inhibitor of the pyrimidine de novo enzyme, dihydroorotic acid dehydrogenase (DHO-DH). In order to determine whether in vitro data could be extrapolated to the in vivo situation we investigated antipyrimidine effects of DUP-785 in mice bearing colon cancer. Two tumor models were used, Colon 26 and Colon 38, resistant and moderately sensitive to DUP-785, respectively. DUP-785 at 50 mg/kg caused a depletion of plasma uridine in mice, and depleted tissue uridine levels in Colon 38 down to 10%, which was retained for several days; in Colon 26 the decrease was less and tissue uridine levels recovered rapidly. In livers of these mice no significant effect on uridine was observed. DUP-785 depleted UTP in bone marrow cells within 2 hr to 25% of control levels, after 4 days normal levels were found. In livers of both Balb-c mice (bearing Colon 26) and C57Bl/6 mice (bearing Colon 38) a small decrease of uridine nucleotide pools was found. In Colon 26 DUP-785 increased uridine nucleotide pools to 170% after 2 hr, at 1 day normal levels were observed, but after 2 days again an increase was found. In Colon 38 DUP-785 decreased the uridine nucleotide pool by 50% after 1 and 2 days. DUP-785 did not affect cytidine nucleotide pools of livers and of Colon 26 and Colon 38. The ratio between uridine nucleotides and cytidine nucleotides decreased from 2.2 to 0.90 in Colon 38, in the other tissues the decrease was less. DHO-DH was measured in bone marrow cells and Colon 26 and 38 before and after treatment. Basal levels of DHO-DH were 3 times higher in Colon 26 than in Colon 38. In treated tumors DHO-DH was initially inhibited by more than 90%, after 7 days enzyme activity in Colon 26 was 50% and in Colon 38 about 200% of basal levels. In bone marrow cells DHO-DH was also rapidly inhibited but recovered within 4 days. It is concluded that the retention of antipyrimidine effects of DUP-785 in Colon 38 were more pronounced than in Colon 26, which is in agreement with the better antitumor effect of DUP-785 in Colon 38.
布喹那钠(DUP - 785)是嘧啶从头合成酶二氢乳清酸脱氢酶(DHO - DH)的强效抑制剂。为了确定体外数据是否能外推至体内情况,我们研究了DUP - 785对荷结肠癌小鼠的抗嘧啶作用。使用了两种肿瘤模型,分别是对DUP - 785耐药的Colon 26和中度敏感的Colon 38。50 mg/kg的DUP - 785使小鼠血浆尿苷耗竭,并使Colon 38的组织尿苷水平降至10%,且持续数天;在Colon 26中,尿苷水平下降较少且迅速恢复。在这些小鼠的肝脏中,未观察到对尿苷有显著影响。DUP - 785在2小时内使骨髓细胞中的UTP降至对照水平的25%,4天后恢复正常水平。在Balb - c小鼠(荷Colon 26)和C57Bl/6小鼠(荷Colon 38)的肝脏中,均发现尿苷酸池略有下降。在Colon 26中,DUP - 785在2小时后使尿苷酸池增加至170%,1天后恢复正常水平,但2天后又再次升高。在Colon 38中,DUP - 785在1天和2天后使尿苷酸池减少50%。DUP - 785不影响肝脏以及Colon 26和Colon 38的胞苷酸池。在Colon 38中,尿苷酸与胞苷酸的比值从2.2降至0.90,在其他组织中下降幅度较小。在治疗前后,对骨髓细胞以及Colon 26和Colon 38中的DHO - DH进行了测定。Colon 26中DHO - DH的基础水平是Colon 38中的3倍。在治疗后的肿瘤中,DHO - DH最初被抑制超过90%,7天后,Colon 26中的酶活性为基础水平的50%,Colon 38中约为基础水平的200%。在骨髓细胞中,DHO - DH也被迅速抑制,但4天内恢复。结论是,DUP - 785在Colon 38中的抗嘧啶作用比在Colon 26中更显著,这与DUP - 785在Colon 38中更好的抗肿瘤效果一致。